Skip To Main Content
Vikas Dandekar on Muck Rack

Vikas Dandekar

Verified
  • Editor, Pharma and Life Science, ET Prime
Mumbai
As seen in: ET Prime, 7@7, Ahmedabad Mirror, Bangalore Mirror, ET Healthworld, ETTech.com, India Times, The Economic Times, The Times of India, Flipboard, Moneycontrol and
Journalist - Indian pharma & healthcare. Views own vikas.dandekar@timesofindia.com
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Vikas

Contact Vikas, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Drug Makers Refuse to Bear Responsibility of Overpricing

|
By Teena Thacker Verified, Vikas Dandekar Verified
| The Economic Times Verified
The Federation of Pharma Entrepreneurs (FOPE) raised concerns that exempting downstream sellers entirely could open the door to disputes and pressure tactics against manufacturers. New Delhi | Mumbai: The Indian pharmaceutical industry, cutting across size, has opposed a regulatory proposal that holds them accountable for overpricing of medicines while exempting retail chemists, hospitals and nursing homes from prosecution and punitive action.
Open in Who Shared View Duplicates (5) Issue with article?

In private healthcare's rise, price points are a big pain

|
By Alenjith K Johny, Vikas Dandekar Verified
| health.einnews.com
The panel, while acknowledging the wide variation in hospital charges across the country, stressed the need for better public health infrastructure, capping fees, and strengthening the cadre of medical specialists. The report, in short, captures the mood of millions of Indians who often face financial distress for treatment at quality private healthcare, which has emerged as a crucial industry over the decades as the state-aided facilities remained relative stragglers or inaccessible.
Open in Who Shared View Duplicates (7) Issue with article?

Thermo Fisher finds India the perfect lab; lab equipment maker steps up investments as drug companies focus on innovation

|
By Vikas Dandekar Verified
| Inkl
Mumbai: Thermo Fisher Scientific, the US-based maker of high-end lab equipment and automation systems, is accelerating investments in India, seeking to capitalise on sharpening focus of homegrown drugmakers on innovative medicines and growing demand for biosimilars. Top executives at Thermo Fisher told ET India has recorded the fastest growth in the Asia-Pacific and Middle East region in the past year, and in the coming five years, the company is expecting double-digit returns from this market.
Open in Who Shared View Duplicates (3) Issue with article?
See all 989 licensed articles (1,498 Total)